被动免疫治疗
尚无关于在人类中针对辛诺柏病毒 (SNV) 进行被动免疫治疗的临床试验。研究显示，如果汉坦病毒心肺综合征患者的中和抗体水平较高，则其存活率更高。[26]Bharadwaj M, Nofchissey R, Goade D, et al. Humoral immune responses in the hantavirus cardiopulmonary syndrome. J Infect Dis. 2000 Jul;182(1):43-8.https://academic.oup.com/jid/article/182/1/43/885927http://www.ncbi.nlm.nih.gov/pubmed/10882580?tool=bestpractice.com 动物模型中的免疫疗法似乎对 SNV 感染有保护作用。[38]Jonsson CB, Hooper J, Mertz G. Treatment of hantavirus pulmonary syndrome. Antiviral Res. 2008 Apr;78(1):162-9.https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2810485/http://www.ncbi.nlm.nih.gov/pubmed/18093668?tool=bestpractice.com
人免疫血浆
已证实，人免疫血浆可使安第斯病毒的病死率从 32% 下降至 14%。[62]Vial PA, Valdivieso F, Calvo M et al. A non-randomized multicentre trial of human immune plasma for treatment of hantavirus cardiopulmonary syndrome caused by Andes virus. Antivir Ther. 2015;20(4):377-86.http://www.ncbi.nlm.nih.gov/pubmed/25316807?tool=bestpractice.com
法匹拉韦
在仓鼠适应性 SNV 感染模型中，试验性抗病毒药物法匹拉韦可减少组织中的病毒抗原水平。[63]Safronetz D, Falzarano D, Scott DP, et al. Antiviral efficacy of favipiravir against two prominent etiological agents of hantavirus pulmonary syndrome. Antimicrob Agents Chemother. 2013 Oct;57(10):4673-80.http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3811478/http://www.ncbi.nlm.nih.gov/pubmed/23856782?tool=bestpractice.com
